FDA clears EarlySense’s Chair Sensor Solution

EarlySense

The US Food and Drug Administration (FDA) has granted marketing clearance to EarlySense‘s Chair Sensor Solution, which continuously monitors patient’s heart rate, respiratory rate and movement.

The EarlySense Chair Sensor is the tool that empowers clinical staff to provide proactive effective, timely interventions when patients are deteriorating or at risk of falling.Recently evaluated at Coffee Regional Medical Center, the Chair Sensor successfully enabled the clinical team to proactively respond to early signs of patient deterioration and to prevent patient falls. This is the first contact free sensor for vital signs in a chair.

“Hospitals have shown us that they value smart beds, now for the first time they can get smart chairs,” said Avner Halperin, CEO of EarlySense. “In addition, with a chair sensor we believe that a number of other clinical environments will open up to the EarlySense System, such as Emergency Departments, Outpatient Clinics and waiting areas where concern around patients may exist and today there is no practical way to monitor patients.”

Peer reviewed clinical trials have shown that responding to early warning signs significantly improve patient safety and hospitals’ economic outcomes. With its continuous patient monitoring feature, the EarlySense Chair Sensor is the tool that empowers clinical staff to provide proactive effective, timely interventions when patients are deteriorating or at risk of falling, therefore, accelerating recuperation and reducing risks.